XML 20 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair value measurements
6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Fair value measurements

5. Fair value measurements

The fair value of the Company’s financial assets and liabilities measured on a recurring basis were as follows:

 

(U.S. Dollars, in thousands)

 

June 30,

2016

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets

 

 

 

 

 

 

 

 

 

 

 

Collective trust funds

 

$

1,599

 

 

$

 

 

$

1,599

 

 

$

 

Treasury securities

 

 

521

 

 

 

521

 

 

 

 

 

 

 

Certificates of deposit

 

 

443

 

 

 

443

 

 

 

 

 

 

 

Derivative instruments

 

 

2,374

 

 

 

 

 

 

2,374

 

 

 

 

Debt securities

 

 

9,438

 

 

 

 

 

 

 

 

 

9,438

 

Total

 

$

14,375

 

 

$

964

 

 

$

3,973

 

 

$

9,438

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred compensation plan

 

$

(1,488

)

 

$

 

 

$

(1,488

)

 

$

 

Total

 

$

(1,488

)

 

$

 

 

$

(1,488

)

 

$

 

 

(U.S. Dollars, in thousands)

 

December 31,

2015

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets

 

 

 

 

 

 

 

 

 

 

 

Collective trust funds

 

$

1,622

 

 

$

 

 

$

1,622

 

 

$

 

Treasury securities

 

 

495

 

 

 

495

 

 

 

 

 

 

 

Certificates of deposit

 

 

337

 

 

 

337

 

 

 

 

 

 

 

Derivative instruments

 

 

2,485

 

 

 

 

 

 

2,485

 

 

 

 

Debt securities

 

 

12,658

 

 

 

 

 

 

 

 

 

12,658

 

Total

 

$

17,597

 

 

$

832

 

 

$

4,107

 

 

$

12,658

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred compensation plan

 

$

(1,503

)

 

$

 

 

$

(1,503

)

 

$

 

Total

 

$

(1,503

)

 

$

 

 

$

(1,503

)

 

$

 

 

Debt Securities

 

On March 4, 2015, the Company entered into an Option Agreement (the “Option Agreement”) with eNeura, Inc. (“eNeura”), a privately held medical technology company that is developing devices for the treatment of migraines. The Option Agreement provides the Company with an exclusive option to acquire eNeura (the “Option”) during the 18-month period following the grant of the Option. In consideration for the Option, (i) the Company paid a non-refundable $0.3 million fee to eNeura, and (ii) eNeura issued a Convertible Promissory Note (the “eNeura Note”) to the Company. The principal amount of the eNeura Note is $15.0 million and interest accrues at 8.0%. The eNeura Note will mature on the earlier of (i) March 4, 2019, or (ii) exercise of the Option. The interest is not due until the note matures and will be forgiven if the Company exercises the option. The investment is recorded in other long-term assets as an available for sale debt security and interest is recorded in interest income.

 

The fair value of the debt security is based upon significant unobservable inputs, including the use of a discounted cash flows model, requiring the Company to develop its own assumptions; therefore, the Company has categorized this asset as a Level 3 financial asset. During the first quarter of 2016, the Company revised the estimated fair value which resulted in an impairment of $0.8 million. During the second quarter of 2016, the Company further revised its estimate based on current financial information and other assumptions.  Revisions to current financial information had a significant negative impact on the valuation of the debt security resulting in an additional impairment of $3.0 million, which the Company recorded in accumulated other comprehensive loss as an unrealized loss on debt securities. The Company continues to classify the impairment as temporary in nature as the Company does not intend to sell the debt security nor does it believe that recoverability of the investment will not occur.

 

The following table provides a reconciliation of the beginning and ending balances for debt securities measured at fair value using significant unobservable inputs (Level 3):

 

(U.S. Dollars, in thousands)

 

 

 

 

Balance at December 31, 2015

 

$

12,658

 

Accrued interest income

 

 

640

 

Unrealized loss on debt securities

 

 

(3,860

)

Balance at June 30, 2016

 

$

9,438